ORIGINAL RESEARCH article
Front. Genet.
Sec. Applied Genetic Epidemiology
Volume 16 - 2025 | doi: 10.3389/fgene.2025.1485855
Nonmetastatic cell 1 gene polymorphisms are associated with the clinical progression and prognoses of patients with colorectal cancer
Provisionally accepted
- 1Fourth Hospital of Hebei Medical University, Shijiazhuang, China
- 2Hebei University, Baoding, Hebei Province, China
- 3Peoples Hospital of Linxi, Xingtai, China
- 4Zhangjiagang City First People's Hospital, Zhangjiagang, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Genetic polymorphisms in the nonmetastatic cell 1 gene (NME1) are reportedly associated with the risk of various tumors and the prognoses of cancer patients. The aims of this study were to evaluate the contribution of two polymorphisms of NME1 to the risk of colorectal cancer (CRC) development and the clinical outcomes of CRC patients in a northern Chinese population.Methods: This study included 453 CRC patients and 464 controls. Genotyping of two polymorphisms (rs2302254 and rs16949649) in the promoter region of NME1 was performed using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method.The results revealed that the rs2302254 and rs16949649 polymorphisms were not associated with the risk of CRC. However, the rs2302254 TT mutant genotype was associated with an increased risk for advanced clinical stage and lymph node metastasis. Moreover, survival analysis revealed that patients with the homozygous mutant TT genotype of rs2302254 had significantly shorter disease-free survival (DFS) and overall survival (OS) times than patients with the homozygous wild-type CC genotype.The rs2302254 polymorphism might function as a potential molecular marker for predicting the progression and prognosis of CRC.
Keywords: NME1, polymorphism, colorectal cancer, risk, prognosis
Received: 25 Aug 2024; Accepted: 28 Apr 2025.
Copyright: © 2025 Liu, Bai, Zhang, Xu and Kong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: De-xian Kong, Fourth Hospital of Hebei Medical University, Shijiazhuang, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.